Dermatologic toxicity in a patient receiving liposomal doxorubicin.
Kristen N
KN
Richards
Rebecca L
RL
Stone
Rashid M
RM
Rashid
Anderson Cancer Center, Department of Dermatology, 515 Holcombe Blvd, Unit 1452, Houston, TX 77030, USA. SusanChon@mdanderson.org.
Susan Y
SY
Chon
D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005076:Exanthema / Q000139:chemically induced*; D005260:Female; D060831:Hand-Foot Syndrome / Q000209:etiology*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects
C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin